Ciron Drugs AND Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Ciron Drugs AND Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 14 Products, $8.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ciron Drugs AND Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 14 Products, $8.7M Trade | TransData Nexus

Ciron Drugs AND Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Corticosteroids Specialist · $8.7M Total Trade · DGFT Verified

Ciron Drugs AND Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $8.7M across 14 products in 10 therapeutic categories. Based on 561 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Hydrocortisone ($3.1M), Clotrimazole ($1.5M), Gentamicin ($1.3M).

Ciron Drugs AND Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Ciron Drugs AND Pharmaceuticals Private Limited pharmaceutical export portfolio — 14 products across 10 therapeutic categories. Source: Indian Customs (DGFT).

Who is Ciron Drugs AND Pharmaceuticals Private Limited? — Company Overview & Market Position

Ciron Drugs and Pharmaceuticals Private Limited, established on June 4, 1990, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24246MH1990PTC056735.

The authorized share capital of Ciron Drugs is ₹10 million, with a paid-up capital of ₹8.3 million. The company operates under the ownership of its directors, including Keyur Ratanshi Shah, Kirti Talakshi Shah, Samir Ratanshi Shah, Dhaval Kirti Shah, and Keyur Ratanshi Shah. Ciron Drugs maintains an active status and is registered with the Registrar of Companies in Mumbai.

What Does Ciron Drugs AND Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Hydrocortisone$3.1M 2Clotrimazole

Product Portfolio — Top 14 by Export Value

Ciron Drugs AND Pharmaceuticals Private Limited exports 14 pharmaceutical products across 10 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Hydrocortisone	Corticosteroids	$3.1M	138	4.7%	4
2	Clotrimazole	Antifungals	$1.5M	98	1.6%	12
3	Gentamicin	Antibiotics	$1.3M	127	2.6%	8
4	Quinine	Antimalarial & Antiparasitic	$682.7K	27	3.5%	4
5	Diphenhydramine	Antihistamines & Allergy	$449.0K	28	1.4%	13
6	Diazepam	CNS & Psychiatric	$386.6K	28	5.2%	4
7	Methylprednisolone	Corticosteroids	$281.7K	16	1.0%	15
8	Griseofulvin	Advanced Antifungals	$241.6K	15	0.7%	14
9	Nitroglycerin	Cardiovascular	$181.0K	13	1.9%	9
10	Metoclopramide	Gastrointestinal	$176.3K	37	0.8%	12
11	Mebendazole	Antimalarial & Antiparasitic	$166.1K	9	1.2%	14
12	Fentanyl	Analgesics & Antipyretics	$127.5K	9	3.4%	8
13	Sulfasalazine	Gastrointestinal	$76.5K	5	2.4%	9
14	Digoxin	Cardiovascular	$41.9K	11	1.9%	8

Ciron Drugs AND Pharmaceuticals Private Limited exports 14 pharmaceutical products across 10 therapeutic categories with a total export value of $8.7M. The top category is Corticosteroids (38.6% of portfolio), followed by Antifungals (16.8%), indicating a concentrated portfolio with the top 5 products accounting for 80.7% of total export value.

Ciron Drugs AND Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Ciron Drugs operates two fully automated manufacturing plants located in Tarapur and Palghar, Maharashtra. These facilities are equipped with cutting-edge machinery and adhere to stringent quality control measures to ensure the production of high-quality pharmaceutical formulations. The plants are certified for Good Manufacturing Practice (GMP) standards, including WHO GMP and cGMP norms as per the Revised Schedule M by the Drug Controller General of India.

3Key Leadership

The leadership team at Ciron Drugs is headed by Managing Director Keyur Ratanshi Shah, who has been with the company since its inception. Other key executives include Kirti Talakshi Shah, Samir Ratanshi Shah, Dhaval Kirti Shah, and Keyur Ratanshi Shah, all of whom hold directorial positions. Their combined experience and strategic direction have been instrumental in the company's growth and expansion in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Ciron Drugs AND Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Ciron Drugs has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and market access in these regions, ensuring compliance with international standards for pharmaceutical products. This expansion reflects Ciron Drugs' commitment to delivering high-quality pharmaceutical formulations to a global clientele.

2Emerging Markets

Ciron Drugs has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), facilitating access to these regions and enhancing its global footprint. This approach underscores Ciron Drugs' dedication to improving healthcare accessibility in developing markets through the provision of quality pharmaceutical products.

3Geographic Strategy

Ciron Drugs demonstrates a diversified geographic strategy by expanding its presence across both developed and emerging markets. This diversification mitigates concentration risk and positions the company to leverage growth opportunities worldwide. The strategic direction focuses on balancing market penetration to achieve sustainable growth and resilience in the global pharmaceutical sector.

Ciron Drugs AND Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Ciron Drugs' manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), indicating compliance with FDA standards for pharmaceutical manufacturing. The company has filed Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) with the FDA, facilitating the approval of its generic pharmaceutical products in the U.S. market. Inspection histories reflect adherence to FDA regulations, ensuring the safety and efficacy of its products.

2WHO & EU GMP

Ciron Drugs' manufacturing facilities are certified for compliance with WHO Good Manufacturing Practice (GMP) standards, ensuring the production of high-quality pharmaceutical products. Additionally, the company holds EU GMP certificates, affirming its adherence to European Union standards for pharmaceutical manufacturing. These certifications underscore Ciron Drugs' commitment to maintaining excellence in manufacturing practices.

3CDSCO & Indian Regulatory

Ciron Drugs AND Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Ciron Drugs operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific competitors are not identified in the available data, Ciron Drugs distinguishes itself through its diversified product portfolio, including corticosteroids, antifungals, and antibiotics, which collectively constitute a significant portion of its exports. The company's strategic focus on both developed and emerging markets further enhances its competitive positioning.

2Key Differentiators

Ciron Drugs' key differentiators include its comprehensive product portfolio, adherence to international manufacturing standards, and strategic market diversification. The company's commitment to quality is evidenced by its WHO GMP and EU GMP certifications. Additionally, Ciron Drugs' focus on emerging markets, facilitated by WHO prequalification, enables it to address diverse healthcare needs globally.

3Strategic Position

Ciron Drugs' current strategic direction emphasizes the production of generic pharmaceutical formulations, with a focus on expanding its presence in both developed and emerging markets. The company's future outlook includes exploring opportunities in specialty pharmaceuticals and contract development and manufacturing (CDMO) services, aiming to enhance its market share and operational capabilities.

Buyer Due Diligence Brief — Evaluating Ciron Drugs AND Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Ciron Drugs has demonstrated a strong track record in pharmaceutical manufacturing, with consistent export volumes and adherence to international quality standards. The company's reliability is indicated by its clean regulatory history and certifications from recognized authorities. These factors position Ciron Drugs as a dependable supplier in the global pharmaceutical market.

2Certifications to Verify

Importers should verify the following certifications when considering Ciron Drugs as a supplier:

FDA Facility Registration: Confirm the registration status of Ciron Drugs' manufacturing facilities with the U.S. FDA.

WHO GMP Certification: Ensure the manufacturing facilities are certified for compliance with WHO Good Manufacturing Practice standards.

EU GMP Certification: Verify the EU GMP certification of the manufacturing facilities.

Frequently Asked Questions — Ciron Drugs AND Pharmaceuticals Private Limited

How many pharmaceutical products does Ciron Drugs AND Pharmaceuticals Private Limited export from India?

Ciron Drugs AND Pharmaceuticals Private Limited exports 14 pharmaceutical products across 10 therapeutic categories. The top exports are Hydrocortisone ($3.1M), Clotrimazole ($1.5M), Gentamicin ($1.3M), Quinine ($682.7K), Diphenhydramine ($449.0K). Total export value is $8.7M.

What is Ciron Drugs AND Pharmaceuticals Private Limited's total pharmaceutical export value?

Ciron Drugs AND Pharmaceuticals Private Limited's total pharmaceutical export value is $8.7M, based on 561 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Ciron Drugs AND Pharmaceuticals Private Limited cover?

Ciron Drugs AND Pharmaceuticals Private Limited exports across 10 therapeutic categories. The largest are Corticosteroids (38.6%, 2 products), Antifungals (16.8%, 1 products), Antibiotics (15.5%, 1 products).

Get Full Ciron Drugs AND Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.